Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero

Core Viewpoint - Transgene has strengthened its Scientific Advisory Board by appointing two prominent scientific advisors, Prof. Antoine Italiano and Prof. Ignacio Melero, to enhance its leadership in cancer immunotherapy development [1][2]. Group 1: Company Overview - Transgene is a biotechnology company focused on designing and developing virus-based immunotherapies for cancer treatment, with a clinical-stage portfolio that includes the myvac® platform for individualized neoantigen therapeutic vaccines [10][11]. - The company’s lead asset, TG4050, has shown proof of principle in patients for the adjuvant treatment of head and neck cancers, and it is also developing other viral vector-based assets like BT-001 [10]. Group 2: Scientific Advisors - Prof. Antoine Italiano is a leading medical oncologist with expertise in early drug development and precision medicine, serving as Head of the Department of Medicine at Institut Bergonié and leading the Precision Medicine program at Gustave Roussy [2][3]. - He has been the Principal Investigator for over 50 Phase I trials and more than 40 Phase II and III clinical trials, focusing on immuno-oncology and targeted therapies [3][4]. - Prof. Ignacio Melero is a professor of immunology at the University of Navarra and co-director of the Department of Immunology and Immunotherapy, recognized for his work in cancer immunotherapy and immunostimulatory monoclonal antibodies [5][6]. - He has led over 40 clinical trials in immunotherapy and has published more than 350 scientific articles, receiving an ERC Advanced Grant for his research on mRNA-based immunotherapies [7][8].